Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Therapeutic agents used to inhibit the HIV-1 protease are integral to the effective suppression of HIV virus replication by use of synergistic combination therapy. This is inherently dependent on the achievement of effective plasma concentrations of the drug in its active form, and sustaining such levels for the duration of a dosing interval without exceeding thresholds of toxicity. The issues determining the absorption, biotransformation, distribution to and activity at the intended site, and elimination, are myriad and complex. Studies at molecular, cell, and tissue levels are useful for predicting the possible fate of these agents at in vivo, but the wide interindividual variability shown in whole-body pharmacokinetic studies is illustrative of the difficulty in making general statements rather than more guarded recommendations. This paper summarizes the current state of understanding of the major interactions between protease inhibitors themselves and other important commonly used agents in the management of HIV disease, based on data from clinical pharmacokinetic studies.


Journal article


AIDS Reviews

Publication Date





208 - 217